Understanding spontaneous mitotic crossover by single-cell multi-omics
通过单细胞多组学了解自发有丝分裂交叉
基本信息
- 批准号:10273068
- 负责人:
- 金额:$ 39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAffectAllelesAutomobile DrivingBiochemical ProcessBiological AssayCell DeathCell LineCellsCellular AssayCicatrixDNADNA Double Strand BreakDNA RepairDNA Sequence AlterationDiploidyEmbryoEmbryonic DevelopmentEventGenesGeneticGenomeGenomic InstabilityGenomicsHomologous GeneHumanHybridsLeadLesionMalignant NeoplasmsMammalian CellMapsMeiosisMethodsMitoticMusMutationOutcomePathway interactionsProcessSister ChromatidSumSystemTechnologyTestingTissuesVariantVisionYeastscell typecost effectiveexperiencegenome integritygenome-widehomologous recombinationin vivoknock-downmultiple omicsmutantrepairedscale upsingle cell sequencingtooltranscriptome sequencingtumorigenesis
项目摘要
PROJECT SUMMARY/ABSTRACT
Homologous recombination (HR) is important for repairing DNA double strand breaks (DSB), and thus is an
essential process in embryonic development, meiosis and suppressing tumorigenesis. HR can also be a double-
edged sword: unrepaired breaks lead to cell death; errors by HR, particularly the crossover type, can cause
extensive genome rearrangements. While the biochemical process of HR in the repair of an induced DSB has
been elucidated by various methods, two critical gaps remain regarding spontaneous HR: 1) the lesions driving
spontaneous mitotic HR (e.g. in addition to DSBs, template switching in replication initiated by single-strand nicks
can also promote HR); and 2) HR partner choice that determines whether HR is error-free or not. The two gaps
are inter-related as HR partner choice could depend on the types of initiating lesions. What determines whether
HR is error-free or not is a fundamental question of what governs genome integrity. A major technical roadblock
is the lack of scalable, genome-wide tools for studying rare spontaneous HR events in many mutants. To scale
up genome-wide HR mapping efforts, I developed sci-L3, which enables linear amplification of single-cell
genomes that scales to 1M cells, enabling generating hundreds of single-cell global HR maps per mutant for
thousands of mutants. Moreover, genetic assays require detecting “scars” in the genome as traces of repair (e.g.
in cancer mutational signature studies), which miss 99% of error-free HR between identical sister chromatids.
There is thus a critical need for unbiased global assays that detect both mutational and error-free HR. I recently
addressed this gap by developing sci-L3-Strand-seq as the first scalable mapping tool for HR between identical
sister chromatids. Our central vision is to determine how spontaneous mitotic crossovers cause genome
rearrangements by scalable single-cell assays. In Area1, we will use sci-L3 to explore the full mutant space
in hybrid yeast diploids. By generating HR maps in all the single mutants in a pooled manner (160 single-cell HR
maps/mutant for 6,000 mutants), we can simultaneously test and generate thousands of hypotheses regarding
different lesions and pathways that drive different types of genome instability events genome-wide. In Area2, we
focus on a deciding factor for whether HR is error-free or not: HR partner choice of allelic sister chromatid, allelic
homolog and non-allelic repeats. With sci-L3-Strand-seq, we propose to map all the seven classes of crossover
outcomes in two systems: mammalian cell lines and mouse embryos. In cell lines, we will investigate genome-
wide distributions of both error-free and mutational HR outcomes in the wild-type as well as hundreds of
perturbations of HR-related genes to determine factors affecting HR partner choice including (epi)genomic
contexts, 3D genome organization and HR gene knockdown. We will also develop in vivo sci-L3-Strand-seq/RNA
co-assay to dissect cell-type variation in HR partner choice in mouse embryos. In sum, this proposal pursues
cost-effective, massively parallel and genome-wide mapping of mitotic crossover outcomes as functions of
genetic perturbations and cell types by developing and applying advanced single-cell multi-omics tools.
项目摘要/摘要
同源重组(HR)对于修复DNA双链断裂(DSB)非常重要,因此是一种
胚胎发育、减数分裂和抑制肿瘤发生的基本过程。人力资源也可以是替身-
利剑:未修复的断裂会导致细胞死亡;HR的错误,特别是交叉类型的错误,可能会导致
广泛的基因组重排。而HR在诱导DSB修复过程中的生化过程
已通过各种方法阐明,关于自发性HR仍然存在两个关键差距:1)病变驱动
自发的有丝分裂HR(例如,除了DSB之外,单链缺口启动的复制中的模板切换
还可以促进HR);以及2)决定HR是否无差错的HR合作伙伴选择。两个差距
是相互关联的,因为HR伴侣的选择可能取决于起始病变的类型。是什么决定了
HR是否没有错误是一个基本的问题,什么是管理基因组完整性的。一个主要的技术障碍
缺乏可扩展的、全基因组的工具来研究许多突变体中罕见的自发HR事件。要扩大规模
在全基因组HR图谱的努力下,我开发了SCI-L3,它使单细胞的线性扩增成为可能
可扩展到100万个细胞的基因组,使每个突变体能够生成数百个单细胞全球HR图
成千上万的变种人。此外,基因分析需要检测基因组中的“伤疤”作为修复的痕迹(例如,
在癌症突变特征研究中),在相同的姐妹染色单体之间错失99%的无差错HR。
因此,迫切需要无偏见的全球检测方法,既能检测突变的HR,又能检测无差错的HR。我最近
通过开发SCI-L3-Strand-seq作为第一个可伸缩的人力资源映射工具,解决了这一差距
姐妹染色单体。我们的中心愿景是确定自发的有丝分裂交叉如何导致基因组
通过可扩展的单细胞分析进行重排。在区域1中,我们将使用SCI-L3来探索完整的突变空间
在杂交酵母二倍体中。通过以集合的方式在所有单个突变体中生成HR图(160个单细胞HR
MAP/6,000个突变体),我们可以同时测试和生成数千个关于
不同的损伤和途径在全基因组范围内驱动不同类型的基因组不稳定事件。在区域2中,我们
关注HR是否没有错误的决定因素:HR伴侣选择等位基因姐妹染色单体、等位基因
同源和非等位基因重复。使用SCI-L3-Strand-Seq,我们建议映射所有七类交叉
两个系统的结果:哺乳动物细胞系和小鼠胚胎。在细胞系中,我们将研究基因组-
野生型和数百个野生型的无错误和突变HR结果的广泛分布
人力资源相关基因的扰动,以确定影响人力资源伴侣选择的因素,包括(表观)基因组
背景、3D基因组组织和HR基因敲除。我们还将在体内开发SCI-L3-Strand-Seq/RNA
共同分析小鼠胚胎HR伴侣选择中的细胞类型变异。总而言之,这项建议旨在
有丝分裂交叉结果的成本效益、大规模并行和全基因组作图
通过开发和应用先进的单细胞多组学工具,研究遗传扰动和细胞类型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yi Yin其他文献
Yi Yin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yi Yin', 18)}}的其他基金
Understanding spontaneous mitotic crossover by single-cell multi-omics
通过单细胞多组学了解自发有丝分裂交叉
- 批准号:
10621289 - 财政年份:2021
- 资助金额:
$ 39万 - 项目类别:
Understanding spontaneous mitotic crossover by single-cell multi-omics
通过单细胞多组学了解自发有丝分裂交叉
- 批准号:
10455042 - 财政年份:2021
- 资助金额:
$ 39万 - 项目类别:
Understanding spontaneous mitotic crossover by single-cell multi-omics
通过单细胞多组学了解自发有丝分裂交叉
- 批准号:
10799260 - 财政年份:2021
- 资助金额:
$ 39万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Research Grant